Spero Therapeutics (NASDAQ:SPRO) Receives “Buy” Rating from HC Wainwright

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 338.60% from the stock’s previous close.

SPRO has been the subject of a number of other reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a report on Friday, November 15th. TD Cowen reissued a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Stock Up 0.9 %

Shares of SPRO stock opened at $1.14 on Monday. The stock has a 50 day moving average of $1.25 and a 200-day moving average of $1.33. The firm has a market cap of $62.15 million, a PE ratio of 16.29 and a beta of 0.63. Spero Therapeutics has a 12 month low of $1.01 and a 12 month high of $1.89.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Spero Therapeutics by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after buying an additional 9,675 shares in the last quarter. Virtu Financial LLC bought a new stake in Spero Therapeutics in the first quarter valued at about $31,000. Renaissance Technologies LLC raised its position in Spero Therapeutics by 14.2% in the second quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after purchasing an additional 121,492 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its stake in Spero Therapeutics by 40.6% during the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after purchasing an additional 309,262 shares during the period. Institutional investors and hedge funds own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.